

Sun Pharma launches dry eye treatment with NCELL tech in Canada

27 January 2022 | News

CEQUA's NCELL technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration



Sun Pharma Canada, a wholly-owned subsidiary of Sun Pharmaceutical Industries announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease. CEQUA (cyclosporine ophthalmic solution 0.09 per cent w/v), a calcineurin inhibitor immunomodulator, is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration.

Abhay Gandhi, CEO, North America, Sun Pharma. "This launch is an important milestone for Sun Pharma as we expand our ophthalmics portfolio into Canada and it demonstrates our commitment to providing innovative medicines to support patient and physician choice."

"We are delighted to see a new product now available to the many Canadians suffering from keratoconjunctivitis sicca or dry eye disease," said W Bruce Jackson, MD, former Professor and Chair, Department of Ophthalmology, McGill University and University of Ottawa.